Last $12.41 USD
Change Today -0.01 / -0.08%
Volume 10.7M
BSX On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

boston scientific corp (BSX) Snapshot

Open
$12.49
Previous Close
$12.42
Day High
$12.51
Day Low
$12.28
52 Week High
01/22/14 - $14.08
52 Week Low
12/11/13 - $11.12
Market Cap
16.5B
Average Volume 10 Days
18.5M
EPS TTM
$0.41
Shares Outstanding
1.3B
EX-Date
--
P/E TM
30.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for BOSTON SCIENTIFIC CORP (BSX)

boston scientific corp (BSX) Related Businessweek News

View More BusinessWeek News

boston scientific corp (BSX) Details

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. It offers interventional cardiology products, including coronary stent systems used in the treatment of coronary artery disease; coronary technology products used to treat patients with atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. The company also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters to treat patients with peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat patients with non-vascular disease. In addition, it offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable pacemaker systems, including implantable cardiac resynchronization therapy pacemaker to treat heart failure; and medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart comprising radio frequency (RF) generators, steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, the company provides endoscopy products to treat diseases of the digestive and pulmonary systems; stone management products to treat patients with urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products; and devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs. Boston Scientific Corporation was founded in 1979 and is headquartered in Natick, Massachusetts.

23,000 Employees
Last Reported Date: 02/26/14
Founded in 1979

boston scientific corp (BSX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $900.0K
Executive Vice President of Global Operations...
Total Annual Compensation: $517.7K
Executive Vice President and President of Asi...
Total Annual Compensation: $537.3K
Chief Administrative Officer, Executive Vice ...
Total Annual Compensation: $612.0K
Compensation as of Fiscal Year 2013.

boston scientific corp (BSX) Key Developments

Boston Scientific Corporation Receives CE Mark for Vercise Deep Brain Stimulation System for Treatment of Tremor

Boston Scientific Corporation has received CE Mark for the Vercise Deep Brain Stimulation (DBS) System for the treatment of tremor, including the most common form of this movement disorder known as essential tremor (ET). Tremor is characterized by involuntary and rhythmic shaking, usually associated with difficulty in an activity such as writing or holding and controlling items. Experts say ET may be as much as 20 times more prevalent than Parkinson's disease. The Vercise DBS System is the first system designed to offer precise neural targeting, allowing physicians to customize therapy for patients with ET. It also features a rechargeable battery that can last up to 25 years. One of the first commercial implantations of the Vercise DBS System for ET was performed at the University Hospital Cologne, Germany, by a team of physicians, led by Prof. Dr. Veerle Visser Vandewalle, Head of the Department of Stereotaxy and Functional Neurosurgery, and Prof. Dr. Lars Timmermann, neurologist and professor of Neurological Movement Disorders.

Boston Scientific Corporation Announces New Data from the Clinical Trial Program of the Lotus(TM) Valve System

Boston Scientific announced new data from the clinical trial program of the Lotus(TM) Valve System continue to demonstrate strong performance as a less invasive treatment for patients with severe aortic stenosis who are considered high risk for surgical valve replacement. Data from the REPRISE II clinical trial confirmed safety and effectiveness out to one year, with more than 86% of patients exhibiting a complete absence of paravalvular aortic regurgitation (leaking) and no patients demonstrating moderate or severe paravalvular aortic regurgitation. New data from the REPRISE I and REPRISE II clinical trials were presented at the 26th Transcatheter Cardiovascular Therapeutics (TCT) meeting, the annual scientific symposium of the Cardiovascular Research Foundation. REPRISE II is an ongoing prospective, single-arm, multi-center study designed to evaluate safety and performance of the Lotus Valve System for symptomatic patients with severe calcific aortic stenosis who are considered high risk for surgical valve replacement. The study enrolled 120 patients at 14 sites in Australia, France, Germany and the UK. REPRISE II data build on the positive findings from REPRISE I, a prospective, single-arm, feasibility study that evaluated 11 patients. The REPRISE I two-year results also demonstrated no instances of moderate or severe paravalvular leak and no instances of death. Additionally, patients who received the Lotus Valve System had durable and significant improvements in valve area, transvalvular pressure gradients and New York Heart Association classification compared to baseline.

Boston Scientific Corporation Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-17-2014 10:40 AM

Boston Scientific Corporation Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-17-2014 10:40 AM. Venue: Bank of America Merrill Lynch Financial Centre, London, United Kingdom. Speakers: Michael Onuscheck, senior vice president and president, Europe, Susan Vissers Lisa, Vice President of Investor Relations.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BSX:US $12.41 USD -0.01

BSX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $113.70 USD -1.31
Coloplast A/S kr488.20 DKK +5.70
Olympus Corp ¥4,000 JPY +40.00
St Jude Medical Inc $62.24 USD -1.22
Terumo Corp ¥2,637 JPY +12.00
View Industry Companies
 

Industry Analysis

BSX

Industry Average

Valuation BSX Industry Range
Price/Earnings 69.3x
Price/Sales 2.3x
Price/Book 2.5x
Price/Cash Flow 24.8x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.